Page 16 - Sun Pharma

Sun Pharma says need more clarity from Sebi about whistle-blower complaint

Sebi has received a 150-page letter in which a whistle-blower has accused the company of committing corporate governance and tax-related lapses, besides other securities market-related violations

Sun Pharma slips 8% as Sebi starts probe; may reopen insider trading case

The stock settled 8% lower at Rs 455 on the BSE on reports that the market regulator Sebi has initiated an inquiry into the affairs of pharma major on the basis of a whistle-blower complaint.

Sun Pharma gets US FDA approval for generic Ganirelix Acetate injection

The generic version is therapeutic equivalent to Organon's Ganirelix Acetate injection, 250 mcg/0.5 ml

Sebi starts probe against Sun Pharma, to also reopen insider trading case

The whistle-blower accused the company of committing corporate governance and tax-related lapses, besides other securities market-related violations

Sebi may reopen Sun Pharma insider trading case, probe promoters' lapses

According to sources, alleged irregularities by the company's promoters and others in raising funds through FCCBs are also likely to be investigated by the watchdog

Sun Pharma: Governance issues, margin pressures expected to weigh on stock

Sun Pharma's outlook remains muted amid multiple negatives

Sun Pharma shares continue to decline

Sun Pharma stock is yet to recover from Wednesday's fall on the bourses when it hit a six-month low after a foreign brokerage firm raised concerns around corporate governance practices

Sun Pharma hits 5-month low; stock slips 7%

The stock dipped 7% to Rs 475, its lowest level since June 6, 2018 on the BSE.

Sun Pharma to acquire Japan's Pola Pharma for $1 million for derma products

Sun Pharma Monday said it will acquire Japan-based Pola Pharma for around USD 1 million to strengthen its presence in dermatology segment across the globe. The company has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan, Sun Pharmaceutical Industries said in a statement. Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables. It also has R&D capabilities to develop new technologies and formulations. "This acquisition is in line with our strategy to strengthen our global dermatology presence. Pola Pharma is a leading dermatology company and it will help us launch our speciality and generic dermatology products in the Japanese market in future," Sun Pharma Executive Vice-President Kirti Ganorkar said. Sun Pharma Japan Country Head .

Sun Pharma, subsidiary enter settlements in Modafinil antitrust litigation

The company, however, did not disclose the details of the settlement, saying the terms are confidential

Growth concerns resurface for Sun Pharma after disappointing second quarter

Analysts cut earnings estimates on muted India business growth outlook, rising expenses on specialty launches in the US

Sun Pharma hits three-month low post Q2 results; drops 10% in three days

The stock was down 5 per cent at Rs 533, trading at its lowest level since July 17, 2018, on BSE.

One-time litigation loss, slow domestic business drag Sun Pharma Q2

Company misses revenue estimates too, delivering a top line of Rs 69.37 bn, up a moderate 4.3%. Analysts had expected double-digit revenue growth for the quarter

Sun Pharma's Q2 show marred by one-offs; US growth to drive earnings

Domestic growth is likely to remain firm going ahead, while US growth led by new launches and speciality products should drive earnings

India biz may stabilise in FY19, but govt price caps a concern: Sun Pharma

The company's India business revenues stood at Rs 80.29 billion in 2017-18, a growth of 4 per cent over 2016-17

Sun Pharma looks to grow complex generics, specialty products biz faster

This strategy will entail taking multiple initiatives, both organic and inorganic as well as assuming measured risks

Sun Pharma gets Australian health regulator's nod for plaque psoriasis drug

ILUMYA is one of the key specialty products of Sun Pharma and it was approved by the US health regulator USFDA in March 2018 while the European Commission approved it in September 2018

First USFDA approval for Sun Pharma's Halol plant after warnings

This speciality drug, Sun claimed, is the first and only form of latanoprost that is not formulated with benzalkonium chloride

Sun Pharma shares gain 4% after declining 7% in past three days

The stock has moved higher by 4% to Rs 655, bouncing back 6% from its early morning low of Rs 620 on the BSE on Wednesday.

Sun Pharma's Halol plant is in trouble yet again, gets USFDA observations

Halol, a key plant for the drug maker to manufacture injectables and specialty drugs, was under regulatory scanner since 2014